Cara Therapeutics Secures Swiss Regulatory Approval For Chronic Kidney Disease Candidate
The Swiss Agency for Therapeutic Products (Swissmedic) has approved Cara Therapeutics’ (NASDAQ: CARA) lead candidate KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult hemodialysis patients.
